Table 1 Baseline characteristics
All population (n = 130) | AMI (n = 25) | Myocarditis (n = 52) | Perimyocarditis (n = 24) | Takotsubo CMP (n = 21) | Unclear dg (n = 8) | p among groups | |
|---|---|---|---|---|---|---|---|
Clinical characteristics | |||||||
Age (years) | 48.7 ± 18,0 | 55.9 ± 14.9 | 41.6 ± 15.8 | 38.0 ± 17.3 | 66.2 ± 11.5 | 58.2 ± 8.9 | <0.001* |
Female (n) | 57 (41.9%) | 16 (64.0%) | 14 (26.9%) | 5 (20.8%) | 18 (85.7%) | 2 (25.0%) | <0.001* |
BMI (kg/m2) | 27.0 ± 5.1 | 27.8 ± 6.8 | 27.6 ± 5.0 | 24.6 ± 3.6 | 26.7 ± 4.1 | 28.1 ± 3.9 | 0.062 |
Hypertension (n) | 43 (33.1%) | 12 (48.0%) | 8 (15.4%) | 5 (20.8%) | 15 (71.4%) | 3 (37.5%) | <0.001* |
DM (n) | 11 (8.5%) | 3 (12.0%) | 3 (5.8%) | 1 (4.2%) | 3 (14.3%) | 1 (12.5%) | 0.640 |
Dyslipidemia (n) | 22 (16.9%) | 8 (32,0%) | 5 (9.6%) | 3 (12.5%) | 4 (19%) | 2 (25.0%) | 0.170 |
Smoking (n) | 37 (28.5%) | 10 (40.0%) | 13 (25.0%) | 9 (37.5%) | 4 (19.0%) | 1 (12.5%) | 0.296 |
Laboratory | |||||||
CK (μkat/l) | 15.1 ± 59.0 | 8.3 ± 6.7 | 24.1 ± 92.9 | 13.7 ± 13.1 | 3.5 ± 2.1 | 13.9 ± 16.0 | 0.007 |
CK-MB (μkat/l) | 0.94 ± 0.89 | 0.93 ± 0.78 | 0.95 ± 0.85 | 1.00 ± 1.07 | 0.63 ± 0.45 | 1.43 ± 1.46 | 0.847 |
Troponin T (μg/l) | 0.95 ± 1.07 | 1.44 ± 1.49 | 0.77 ± 1.61 | 1.37 ± 1.42 | 0.60 ± 0.73 | 0.34 ± 0.50 | 0.001* |
NT-pro-BNP (ng/l) | 1891 ± 4762 | 1880 ± 3158 | 1663 ± 6227 | 895 ± 1095 | 3999 ± 5107 | 212 ± 169 | 0.190 |
CRP (mg/l) | 42.9 ± 50.0 | 21.0 ± 28.9 | 46.2 ± 55.6 | 82.2 ± 76.2 | 15.3 ± 30.4 | 21.9 ± 52.1 | <0.001* |
Echocardiography | |||||||
LV EF (%) | 53.4 ± 11.2 | 53.7 ± 10.2 | 56.1 ± 10.4 | 53.6 ± 10.3 | 42.2 ± 10.3 | 61.3 ± 7.9 | <0.001* |
WM abnormalities (n) | 62 (49.2%) | 18 (72.0%) | 16 (31.4%) | 11 (45.8%) | 16 (88.9%) | 1 (12.5%) | <0.001* |
Coronary angiography | |||||||
Coronary AS (n) | 43 (35.8%) | 11 (44.0%) | 12 (25.5%) | 3 (15.8%) | 12 (57.1%) | 5 (62.5%) | 0.011* |
LV EF (RLVG) (%) | 51.3 ± 13.7 | 56.0 ± 11.0 | 55.9 ± 13.0 | 51.6 ± 11.9 | 37.6 ± 9.4 | 60.0 ± 9.4 | <0.001* |